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Introduction

The importance of the relationship between bacteria and the pathogenesis
of pulpal and periradicular disease has been well established by numerous
studies (Kakehashi et ai, 1965; Sundqvist, 1976; Patterson, 1976; Moller, 1981).
Pulpal infections initially produce an inflammatory response within the pulp that
often leads to complete pulpal necrosis and subsequently, in the periapical
region, which results in lesion formation with local bone destruction (Bergenholtz,
1990). The bacteria from infected root canals have been extensively studied and
shown to be predominantly gram-negative and strictly anaerobic (Fabricius,
1982; Farber and Seltzer, 1988).

Bacterial lipopolysaccharide (LPS) is an

endotoxin and a major component of the outer membrane of gram-negative
bacteria. It is a complex glycolipid composed of a hydrophilic polysaccharide
moiety and a hydrophobic domain known as Lipid A.

It is also one of the most

potent microbial initiators of inflammation (Raetz, 1990; Cohen 2002) and
endodontic pathogenesis (Dwyer and Torabinejad, 1981). A positive correlation
has been reported between the levels of LPS in root canals and the presence of
periapical lesions (Dahlen and Bergenholtz, 1980; Schonfeld et a/1982).
Cells of the host's immune response system may detect and respond to
bacteria and their byproducts.

Although these products have structural

sequences that are unique to strain and species specific variations, they also
have a highly conserved and common molecular pattern that does not vary
between microbes.

This is called the pathogen associated molecular pattern
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(PAMP) (Janeway, 1989). LPS represents the PAMP in gram-negative bacteria
and the Lipid A segment is the invariant portion that is responsible for its proinflammatory effects. Host immune cells recognize PAMP through a family of
proteins known as Toll-like receptors (TLRs) which are an essential part of the
recognition and signaling component of the mammalian host defense system
(Akira, 2001).

Human TLR4 was the first TLR to be described.

It is

predominantly expressed in immune cells, and has now been established as the
receptor for LPS (Medzhitov et aI, 1997). Once LPS passes through the apical
foramen and into the periradicular tissue where it binds its receptor, it starts a
cascade that leads to NF-kB activation of numerous inflammatory genes that
result in cytokine production, which subsequently initiate and sustain many of the
bone osteolytic events in endodontic disease (Stashenko, 1998). It has been
shown that LPS can directly stimulate osteoblasts to express RANKL, resulting in
osteoclast formation (Kikuchi et aI, 2001). Recent findings have also indicated
that LPS may be directly involved in osteoclast differentiation (Suda et al., 2002;
Jiang et al., 2006). NFATc1 has been shown to be a key regulator of
osteoclastogenesis and plays a critical role in the terminal differentiation of
osteoclasts (Takayanagi et al., 2002). Once differentiated and activated, mature
osteoclasts can act to resorb bone in this specialized microenvironment resulting
in apical lesion formation (Dahlen, 1981).
Researchers have identified a series of cytokines that are produced by
both inflammatory and non-inflammatory host cells that are involved in the bone
resorptive process (Stashenko, 1994; Fouad, 1997; Stashenko, 1998). These
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cytokines include IL-1a, IL-1j3, TNF-a, IL-6, and IL-11 (Stashenko, 1994;
Manolagas, 1995; Kawashima and Stashenko, 1999).

It has also been

demonstrated that when an infected root canal is thoroughly cleaned and
debrided, rendering it free from bacteria and bacterial byproducts, pulpal and
periapical inflammatory responses cease to occur and the damaged tissues heal
themselves (Moller et aI, 1981).
RNA interference (RNAi) is emerging as a new and potent method of gene
silencing that selectively targets and shuts off the post-transcriptional expression
of mRNA (Elbashir et al., 2001). In an effort to determine the implication of small
interfering RNAs (siRNAs) for the inhibition of LPS-induced osteoclast formation
and cytokine stimulation, the objective of this study was to suppress TLR4 or
NFATc1 expression in monocytes and osteoclast cells using the RNAi technique.
We hypothesized that knocking down the expression of TLR4 and NFATc1 in
these cells with effective siRNA will modulate the effects of LPS stimulation.
Thus, this study aimed to provide a potential therapeutic approach and open new
horizons in the field of endodontic research.
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Review of Literature
Etiology of Apical Periodontitis
Apical periodontitis is a local inflammatory destruction of the bone and
periodontium around the apex of a tooth in response to an infection of endodontic
origin (Moller et al. 2004).

Although chemical and physical factors can also

induce a peri radicular inflammatory response, evidence for the essential role of
microbial agents in dental pulp infection and the pathogenesis of apical
periodontitis is overwhelming and well-established (Kakehashi, 1965; Sundqvist,
1976; Moller, 1981).
The presence of bacteria in the necrotic dental pulp of teeth with
associated pathologic conditions was reported more than a century ago, when
Miller {1894} hypothesized that microorganisms are the causative agents of
endodontic disease (Miller, 1894). However, it was not until a half century later,
when the causal relationship between periapical inflammation and bacterial
infection was convincingly demonstrated. In the classic study by Kakehashi et al.
{1965}, it was shown that pulpal necrosis and periapical inflammation developed
in rats subjected to mechanical pulp exposure and kept exposed to the
conventional microbial environment of the oral cavity.

Conversely, germ-free

animals demonstrated minimal pulpal inflammation and no periapical destruction,
and formed reparative dentin at the exposure sites, exhibiting the substantial
healing capability of the pulp in the absence of infection (Kakehashi 1965).
Subsequent animal and human studies confirmed the cause and effect
relationship between pulpal infection and periapical pathology.
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In his thesis, Sundqvist (1976) observed 32 traumatized incisors with
pulpal necrosis, yet clinically intact crowns. Eighteen of the 19 (95%) teeth with
associated periapical lesions presented with positive cultures for bacteria that
were predominantly strict anaerobes, whereas no bacteria were cultivated from
the 13 teeth without periapical lesions (Sundqvist, 1976). In a controlled monkey
experiment in which the pulps of 26 teeth were rendered necrotic under sterile
conditions and immediately sealed in the uninfected root canal, none developed
apical periodontitis, even after 6-7 months of observation. In contrast, 47 of the
52 (90%) teeth in which the pulps were deliberately infected prior to sealing of
the access opening, exhibited periapical destruction (Moller et al., 1981). This
study demonstrated that apical periodontitis can not be caused by necrotic pulp
tissue per se, via toxic tissue breakdown products, but that the presence of
bacteria within the pulp appears to be an absolute requirement for the
development of periradicular disease.

Studies on Endodontic Flora and Routes of Entry
There are several pathways by which microorganisms may gain entry into
the dental pulp. The most common may be through openings in the dental hard
tissues as a result of the caries process, operative procedures, and traumainduced micro-cracks. Anachoresis, which is the transport of microorganisms via
blood circulation to the area where they establish an infection, has also been
proposed in cases where teeth with necrotic pulps and clinically intact crowns
were observed (Robinson and Boling, 1941; Gier and Mitchel, 1968). However,

5

this theory remains controversial and the extent to which this may occur is
unknown (Oelivanis and Fan, 1984).

Another possible pathway for bacterial

invasion and infection of the pulp may be through exposed dentinal tubules or
accessory canals found at the cervical root surface in the periodontal pocket,
although the importance of this pathway has also been debated (Seltzer et al.,
1963; Mazur and Massier, 1964).
Over 500 bacterial species are currently recognized as normal inhabitants
of the oral cavity and an additional 200 may still be detected by molecular
methods (Moore and Moore, 1994; Munson et al., 2002). Although all have the
theoretic capability and potential to invade and infect the pulp, induce periapical
inflammation and bone destruction, only a small proportion of species have been
consistently isolated from such root canals (Sundqvist, 1994).
The necrotic root canal system provides a unique ecological niche for
bacteria. The lack of oxygen supply, availability of host tissues, and inflammatory
exudates produced at the bacteria-inflammatory tissue interface are the primary
nutritional factors selecting for bacterial growth (Sundqvist, 1992). Studies have
shown that the relative proportion of obligate anaerobes increases, and that of
facultative bacteria decreases, with time elapsed after infection (Fabricius et al.,
1982; Tani-Ishii et ai, 1994). Bacteriologic sampling of necrotic root canals of
chronically infected teeth with primary apical periodontitis indicate that the
microbial

population

is

predominantly

anaerobic

and

Gram-negative

(Bergenholtz, 1974; Sundqvist, 1976). Most of these species have also been
identified in periodontal pockets (Moore, 1987; Socransky et al., 1988). The
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anaerobic infection is usually polymicrobial, typically containing between 2 to 8
species, with no more than 20 species having ever been found in one root canal
(Dahlen and Haapasalo, 1998). Common species that have been isolated in
both

human and animal studies include Fusobacterium,

Streptococcus,

Prevotella, Eubacterium, Peptostreptococcus, Camphylobacter, Porphyromona,
and Propionibacterium (Sundqvist, 1994).
Bacterial interactions playa significant role in determining the composition
and pathogenicity of the root canal flora. Virtually all microbes that are present in
root canals have the potential to initiate a periapical reaction and bone
destruction (Sundqvist, 1976). However, some combinations have a tendency to
associate together, providing for a mutually supportive (synergistic) environment,
whereas others may create negative (antagonistic) associations by competing for
nutrients, thus inhibiting the growth of other bacteria (Greiner and Mayrand,
1986; Sundqvist 1992).

In studies conducted by Fabricius et al., bacteria

originally isolated from the root canals of monkeys with periapically involved teeth
were then inoculated in various combinations or as individual strains into the root
canals of other monkeys. Infection of root canals with individual bacterial species
produced a relatively mild periapical inflammation and little periapical destruction,
whereas in combinations, the same bacterial species were highly pathogenic and
capable of inducing more severe periapical reactions and larger areas of
periapical destruction (Fabricius et a/., 1982b). These observations and later
studies have confirmed that the virulence of individual species may vary
considerably and highlight the importance of microbial synergy for the
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pathogenicity of the endodontic flora (Dahlen et al., 1987).

The pathogenic

properties of these microorganisms are affected by a variety of factors which
include: (1) the presence in sufficient numbers to initiate and maintain infection,
(2) the ability to acquire nutrients from the host tissue for growth and survival, (3)
the ability to evade, withstand, and/or alter host defenses, and (4) the synthesis
and release of a variety of virulence factors including proteolytic enzymes,
metabolites, and cell wall components-such as endotoxin (lipopolysaccharide,
LPS) from Gram-negative bacteria and proteoglycans from Gram-positive
bacteria--into the periapical area where they are capable of damaging host
tissues (Horiba et al., 1991; Hashioka et al., 1994). LPS, in particular, is the best
studied of these virulence factors, and has also been identified as a highly potent
initiator of inflammation and a major factor in bone resorption (Dwyer and
Torabinejad, 1981; Dahlen et al., 1981; Schonfeld et al., 1982).

Bacterial Endotoxin-Lipopolysaccharide (LPS)
Structure

Bacterial lipopolysaccharide (LPS) is a fundamental component of the cell
wall of Gram-negative organisms (Figure 1). One bacterial cell contains
approximately 106 LPS molecules, occupying roughly 75% of its outer membrane
(Nikaido, 1996). Although there is a great compositional variation among
lipopolysaccharides derived from different groups of Gram-negative bacteria,
they all have a common basic structure. They are complex glycolipids, consisting
of a hydrophilic heteropolysaccharide and a covalently bound hydrophobic lipid
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domain known as lipid A (Luderitz et a/. , 1982). The heteropolysaccharide part
can be divided into two subdomains, the O-specific polysaccharide chain and the
core glycolipid (Figure 2). Lipid A serves as the base structure which secures the
LPS molecule within the bacterial membrane, while the polysaccharide
component interacts with the external environment.
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Figure 1. General structure of a Gram-negative bacterial cell wall. The inner and outer
membrane are separated by a periplasmic space which contains peptidoglycan.
Lipopolysaccharide (LPS) is found in the outer membrane and consists of three parts: Lipid A,
core glycolipid, and O-specific chain. Kdo forms a covalent bond between the core and lipid A.
Image modified from : edoc.hu-berlin.deI.../HTMLlchapter1.html
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Gram-negative bacterial endotoxin (lipopolysaccharide, LPS)
Core glycolipid
O-specific polysaccharide chain

O-specific
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Figure 2. General chemical structure of lipopolysaccharide showing the O-specific chain, core
glycolipid (composed of inner and outer regions), and lipid A. Image obtained from:
frees pace. virg in.netlr.barclay/edtxsch1.htm

O-specific Chain (O-antigen)
The O-specific chain is a complex polysaccharide composed of one to
eight repeating units of identical glycosyl residues. There are enormous structural
diversities in O-chains. The length, linkages, and fine structure of the O-chain
structure vary from strain to strain, functioning as an important surface antigen,
and thus define the serotype specificity of LPS and each bacterial strain
containing them (Rietschel et al., 1991). The O-antigen possesses several
intrinsic biological activities and although it's not required for growth in-vitro, its
presence is known to help bacteria evade the host immune system and other
environmental disturbances (Rietschel et al., 1992). However, not all Gramnegative bacteria possess an O-specifc chain.

Such mutants produce rigid,

rough-looking colonies when grown on solid agar and are accordingly termed
"rough" (R) , whereas wild-type bacterial species containing the O-antigen form
colonies with a smooth morphological appearance and are termed "smooth" (S).
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Core Region

The core region of LPS can be subdivided into an outer and inner region
(Figure 1). Although it is structurally more uniform than the O-chain, some
structural variances are found, mainly in the outer core. The outer core region
usually consists of common hexose residues such as D-glucose, D-galactose,
and N-acetyl-D-glucosarnine.

The proximal inner part of the core region is

composed of specific a heptose residue, primarily in the L-glycero-D-manno
configuration, and 3-deoxy-D-manno-oct-2-ulopyranosonic acid (Kdo) (Holst and
Brade, 1992). Although core regions may vary among bacterial species, the
inner core region containing Kdo appears to be well conserved among all Gramnegative bacteria, as Kdo forms the linkage by which the core is covalently
bound to lipid A (Caroff et a/., 2002). It has long been believed that the minimal
LPS structure required for viability of Gram-negative organisms consists of lipid A
linked to only two Kdo residues (Raetz, 1990; Schnaitman and Klena, 1993),
however viable mutants lacking Kdo and with the basic tetra-acyl form of lipid A,
termed lipid IVa, have recently been experimentally produced.

These results

suggest that lipid IVa may indeed be the actual minimal LPS structural
requirement (Meredith et a/' 2006). It is unclear what, if any biologic activities
J

the outer core region of LPS is responsible for, however, it is thought that both
the inner and outer core contain epitopes that are recognized by host antibodies
(Rietschel et a/' 1992).
J
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Lipid A

Lipid A is a unique and distinctive glucosamine-based phospholipid that
anchors LPS to the outer membrane of the gram-negative bacterial cell wall
(Raetz, 1990).

It is generally composed of a phosphorylated

~ 1,6-linked

0-

glucosamine disaccharide that carries up to six or seven fatty acid chains
(Zahringer et., al 1999). It, along with the Kdo-containil1g inner core region,
represents the most structurally conserved region among all Gram-negative
species (Figure 3). However, variations can occur in the fine structure, arising
from differences in the length, position, and number of the acyl groups.

Kdo;a,lipid A
(Re Endotoxin)

14

14

14

14

Figure 3. Structure of Kdo(2)-lipid A found in E.coli, similar to that found in most pathogenic
Gram-negative bacteria. Image from: www.lipidlibrary.co.uklLipidsllipidAiindex.htm

It has been demonstrated that lipid A is the region of LPS that is
responsible for many of the pathologic effects associated with Gram-negative
bacterial infection, since free lipid A has been shown to reproduce the toxic
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effects of LPS (Galanos et al., 1985). Additional studies have confirmed the role
of lipid A by using chemically synthesized homologues and partial structures that
were able to produce identical effects (Kusumoto et al., 1984; Imoto et al., 1987).
This structure, called compound 506, was shown to be identical to E. coli lipid A
purified in a variety of biological assays, and was able to optimally express a full
spectrum of endotoxic activities (Galanos et al., 1985; Kotani 1985). Based on
these findings it was concluded that the cytokine inducing capacity of compound
506 was solely attributed to its three dimensional structure, and that the natural
form

of

this

compound

represents

the

optimal

configuration

for

immunostimulatory effects.
Host Response

When describing the effects of LPS on the host's tissues, perhaps the
author Lewis Thomas stated it best in The lives of a Cell: "This oppressive
uncontrolled and autodestructive behavior of the host is what makes endotoxin a
venom ...... they are read by our tissues as the worst of news .... when we sense
LPS, we will use all the defenses at our disposal to bomb, block, seal off, and
destroy all tissues in the area" (Thomas, 1974). Since that time, much has been
studied about the structure and basic principles of LPS bioactivity and its
mechanism of action are now well understood (Raetz et al., 1991; Galanos and
Freudenberg, 1993).

When Gram-negative bacteria die or multiply, LPS is

liberated and released into the host tissue where it can initiate an inflammatory
response (Rietschel and Brade, 1992a; Barthel et al., 1997) and ultimately result
in periapical bone destruction (Stashenko, 1990; Yamasaki et al., 1992). It has
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been thought that most, if not all, of the pathogenic effects of LPS are not direct,
but rather induced indirectly through its interaction with various host cells. LPS
stimulates monocytes, macrophages, and various other host cells to produce and
release a large number of pro-inflammatory cytokines such as tumor necrosis
factor-a (TNF-a), interleukin (IL)-1, IL-6, IL-8, IL-11, and IL-12 as well as a variety
of other small molecules such as lipid mediators, oxygen radicals, and enzymes
(Raetz, 1990; Cohen, 2002). These mediators can then exert either a local or
systemic response by acting independently, sequentially, synergistically or
antagonistically to induce many of the typical effects of LPS (Rietschel and
Brade, 1992a). In addition to its proinflammatory effects, LPS has been shown to
be a potent stimulator of bone resorption by acting on the production and release
of cytokines that influence osteoclast differentiation and activation (Ito et al.,
1996; Kikuchi et al., 2001; Jiang et al., 2003). Particularly, LPS has been
experimentally shown to stimulate tissue destruction and alveolar bone
resorption in vitro using a mouse osteoblast tissue culture (Pelt et al., 2002) and
also in vivo using a rat model (Umezu et al., 1989).
Implication in Endodontic Infections

Numerous studies have reported the presence of LPS in samples taken
from the root canals of necrotic teeth (Schein and Schilder, 1975; Schonfeld et
al., 1982) and the pulpal-dentinal wall of teeth with apical periodontitis (Horiba et
al., 1990). Other studies have confirmed a strong correlation between the levels

of LPS and Gram-negative bacteria found in the infected root canal (Dahlen and
Bergenholtz, 1980). Using a rat model, it was shown that LPS released as a
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result of death or multiplication of bacteria within the root canal can pass through
the apical foramen and into the periapical tissues where they increase in levels
from 1 to 70 days after pulp exposure (Yamasaki et al., 1992). The introduction
of LPS from F. nucleatum into sterile root canals of teeth in monkeys was shown
to induce periapical inflammation and bone resorption (Dahlen et al., 1981).
Similarly, the direct application of S. Minnesota, E. corrodens, and E. coli LPS to
the dental pulp also induced significant bone destruction in dogs (Pitts et al.,
1982; Mattison et al., 1987).
Associations have also been found between the LPS content of infected
teeth with pulp necroses and clinical endodontic symptoms such as spontaneous
pain, tenderness to percussion, and exudation (Horiba et aL, 1991). LPS can
contribute to the release of increased levels of vasoactive and neurotransmitter
chemicals close to nerve endings in the periapical tissues, resulting in pain
(Seltzer and Farber, 1994).
Calcium hydroxide has been shown to inactivate LPS in in vitro studies by
hydrolyzing the highly toxic lipid A component into fatty acids and amino sugars
which are non-toxic molecules (Safavi and Nichols 1993, 1994; Barthel et al.,
1997; Olsen et al., 1999). Silva et al. (2002) carried out a study in dogs in which
they showed that LPS did not induce the formation of periapical lesions in teeth
when combined with calcium hydroxide, confirming the detoxifying role of calcium
hydroxide in vivo.

The above findings, as a whole, strongly support the

connection between LPS and the significant role they play in the pathogenesis of
apical periodontitis.

15

Host Recognition of LPS

The molecular mechanism by which host cells recognize bacterial
components has been extensively studied and vast breakthroughs have been
made in the identification of molecules in the "LPS receptor complex" , which play
a crucial role in recognizing, binding, and mediating the LPS response.

The

specific mechanism involved in recognition of LPS by host cells were first
identified in 1990 (Schumann et a/., 1990; Wright et a/., 1990).

The basic

mechanism is that LPS is first recognized by, and then forms a complex with, the
soluble LPS-binding protein (LBP).

LBP is a lipid transfer molecule that

catalyzes the movement of phospholipids. These LPS/LPB complexes are then
transferred to the membrane bound CD14 receptor, causing a conformational
change, that allows LPS to be transferred to the Toll-like receptor 4 (TLR4) and
myeloid differentiation protein-2 (MD-2) (Hailman et aI., 1994;

Tobias et a/.,

1995) (Figure 4). These three proteins-CD14, TLR4, and MO-2 are referred to
as the "LPS receptor complex".

TLR4 LPS

) 4

LRR

LBP

CDI 4

Cytoplas

Figure 4. Schematic diagram of the LPS
receptor complex.
LPS is recognized by a
complex of three proteins: CD14, TLR4, and
MD-2. LPS is first bound by LBP which then
transfers it to CD 14. CD 14 then presents LPS to
TLR4-MD-2. TLR4 is the actual LPS receptor. It
is a transmembrane protein characterized by an
extracellular domain containing multiple leucinerich repeats (LRR) , a transmembrane domain,
and an intracellular TlR domain. TLR4 mediates
an intracellular signal transduction through three
adaptor proteins including MyD88, TlRAP, and
TRIF. Image obtained from Fujihara et aI, 2003.

Adaplor
proteins
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The LPS receptor com plex
CD14

CD14 is a 55-kDa glycoprotein that can be found in two forms. The first is
a soluble CD14 (sCD14) which can be found in plasma, where they are able to
interact directly with the LPS/LPB complex and enable the activation of LPS
signaling in cells that lack the membrane-bound CD14, e.g. endothelial cells,
fibroblasts, and smooth muscle cells to induce cytokine production (Pugin et al.,
1993; Tapping and Tobias, 1997). The second and more extensively studied
form is the membrane CD14 (mCD14), which is embedded in the plasma
membrane of myeloid cells via a glycosylphosphatidynositol linkage (Haziot et
al., 1988; Wright et al., 1990).

It is composed of 10 copies of a leucine-rich

repeat (LRR) domain. LRRs are commonly found in various proteins that are
involved in substrate recognition and signal transduction (Bell et al., 2003). The
binding of LPS to mCD14 on monocytes and macrophages is essential for their
activation and can significantly reduce the concentration of LPS required for the
stimulation of these cells as compared with LPS alone by 100 to 1000-fold.
Antibodies to CD14 have been shown to significantly inhibit the binding of
LPS/LBP and reduce cytokine production of myeloid cells in response to LPS
(Wright et al., 1990). Additional studies have shown that CD14-knock-out (CD141-) mice are more resistant to LPS-induced lethal shock and produced

significantly decreased levels of cytokines when stimulated with LPS (Haziot et
al., 1996; Moore et al., 2000). Thus, CD14 was originally identified as a specific
receptor for LPS, even though the dependency on CD14 could be partially
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overcome with higher concentrations of LPS (Perera et al., 2001).

However,

since CD14 lacks transmembrane and intracellular domains (Figure 4), it cannot
by itself initiate a signal transduction in response to LPS, and additional
membrane molecules seemed to be necessary for cellular activation. Several
biochemical and genetic studies support the theory that CD14 binds LPS, but
does not participate directly in signaling (Wright, 1999). Subsequent studies have
since shown that TLR4 is the actual signal-transducing receptor for LPS
(Poltorak et aI., 1998).

It now appears that the role played by CD14 in LPS

signaling is to bind LPS and present it to TLR4 and MD-2. Furthermore, CD14
has been shown to participate in recognition of various bacterial components
other than

LPS, including Gram-positive cell-wall components such as

peptidoglycan (Pug in et al., 1994). CD14 appears able to differentiate between
bacterial products and to present them to various TLRs (Muroi et al., 2002).
TLR4

The presence of pattern recognition receptors on immune cells, with the
ability to detect and dispose of infectious microbial pathogens without interfering
with its own host tissues was put forth to describe the basic concept of innate
immunity (Janeway, 1992; Hoffmann et al., 1999). These receptors recognize
bacterial products that often share a common molecular pattern and are highly
conserved among microorganisms, called the pathogen associated molecular
pattern (PAMP), such as LPS in the case of Gram-negative bacteria (Janeway,
1989). It was only in 1996, when a study in Drosophila, which only possess an
innate immune system, led to the discovery of the Toll as an essential receptor
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for host defense against fungal infection (Lemaitre et a/., 1996). To date, at least
10 homologues of Toll, referred to as Toll-like receptors (TLRs) (TLR1-TLR10),
have been identified in mammalian species, and 7 of them (TLR 1, TLR 2, TLR3,
TLR4, TLR5, TLR6, and TLR9) have been shown to be required for the
recognition and signaling of specific microbial components derived from
pathogens including bacteria fungi, protozoa, and viruses (Poltorak et a/., 1998;
Schwandner et a/., 1999; Yoshimura et a/., 1999; Hemmi et a/., 2000; Wyllie et
aI., 2000; Alexopoulou et a/., 2001; Hayashi et a/., 2001; Takeuchi et a/., 2001).

The structural hallmark of all known Toll proteins, which represent type I
receptors are an extracellular domain containing multiple LRRs, a single
transmembrane region, and an intracellular region known as the "TIR" domain
which is homologous to the Drosophila Toll and the mammalian IL-1 receptor
(Gay and Keith, 1991) (Figure 4). The distinct responses to specific microbial
products are a result of minor variances in the extra- and intracellular domains of
TLRs.
The first human TLR to be identified was TLR4, and is predominantly
found on immune cells such as macrophages and dendritic cells. There is now
compelling evidence that TLR4 is in fact an essential signal-transducing receptor
for LPS (Medzhitov et a/., 1997). The establishment of a link between TLR4 and
LPS recognition came through the use of positional cloning studies of the Lps
locus in C3H/HeJ and C57BLl10ScCr mice which are both insensitive to LPS.
The Lps locus contains the Tlr4 gene and both of these mice were shown to have
mutations in this region.

C3H/HeJ mice were shown to have a single point
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mutation in the TIR domain of Tlr4 which causes proline to be replaced with
histidine at position 712 of the polypeptide chain, whereas C57BLl10ScCr mice
were shown to have a null mutation, resulting in total deletion of the Tlr4 gene
(Poltorak et al., 1998; Qureshi et al., 1999). The essential role of TLR4 for LPS
signaling was further confirmed when mice rendered deficient in the Tlr4 gene
(TLR4 knockout mice) where shown to be as insensitive to LPS as C3H/HeJ
mice (Hoshino et al., 1999).

TLR4 mutations are also associated with a

decreased response to LPS in humans (Arbour et al., 2000). Conversely,
transfection of TLR4 in human embryonic kidney cells that were unresponsive to
LPS was shown to restore the LPS response (Chow et al., 1999).
TLR4, however, is not only exclusively involved in enterobacterial LPS
signal transduction.

It is also implicated in the recognition of several other

endogenous and exogenous ligands.

These include heat-sensitive cell-

associated factor derived from Mycobacterium tuberculosis (Means et al., 1999),
Taxol, which is a diterpene purified from the bark of the Western yew (Taxus
brevifolt) (Kawasaki et al., 2000), heat shock protein 60 (Vabulas et al., 2001),

fusion (F) protein of respiratory syncytial virus (Kurt-Jones et al., 2000), as well
as oligosaccharides of hyaluronic acid, heparin sulfate, and fibrinogen (Takeda et
al., 2003).
Ambiguous Role of TLR2

There is a general consensus that TLR2 is involved in the recognition of
components from a variety of microorganisms. These include Gram-positive,
mycobacterial, and fungal compounds such as peptidoglycan, lipoteichoic acid,
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various lipopeptides, and lipoarabinomannan (Lien et a/., 1999). However, TLR2
was also originally believed to be the long sought after LPS receptor. This was
based on several transfection studies that showed that expression of the
mammalian TLR2 in human embryonic kidney cells that were LPS-unresponsive
were now capable of responding to LPS (Kirschning et a/., 1998; Yang et aI.,
1998). However, later studies revealed that overexpression of TLR2 causes cell
lines to become exceedingly sensitive to trace amounts of non-LPS lipopeptide
contaminants that may have been present in the LPS preparations (Heine et a/.,
1999; Takeuchi et a/., 1999; Faure et a/., 2000).

Repurification of LPS

preparations of Sa/monella and E. coli clearly demonstrated that cells are
activated through TLR4 as the principal signal-transducing molecule, and not
TLR2 (Hirschfeld et a/., 2000; Tapping et a/., 2000). Furthermore, similar types
of LPS elicited the same response in TLR2 knockout mice as in wild-type mice
(Takeuchi et a/., 1999).
Adding to the complexity of LPS signaling, it now appears that the
chemical structure of LPS itself may be an important factor in its recognition by
different receptor clusters, resulting in different cellular responses (Hirschfeld et
a/., 2001; Werts et a/., 2001).

Historically, most of the reported studies have

been performed using commercially available preparations of LPS of E. coli or
Sa/monella.

However, recent publications indicate that not all LPS chemotypes

induce signal transduction through TLR4, specifically LPS of Leptospira
in terrogan s, Porphyromonas gingiva/is, and Neisseria meningitidis have been

shown to signal via TLR2 (Werts et a/., 2001; Bainbridge and Darveau, 2001;
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Pridmore et al., 2001). A recent study suggests that the lipid A segment of these
bacterial species may exhibit several chemical modifications, specifically in the
number of acyl chains, which alters the shape of the LPS molecule,
distinguishing them from the typical LPS of Gram-negative bacteria (Netea et al.,
2002). Thus, TLR2 may recognize distinct epitopes within lipid A of L.
interrogans, P. gingivalis, and N. Meningitidis, in addition to other structurally
unrelated components from Gram-positive bacteria.
Although TLRs are believed to be the main receptors involved in LPS
signal transduction, new experiments have identified an additional heterogenous
complex of four proteins that may be involved in LPS recognition and signal
activation.

Using antibodies against Hsp70, Hsp90, CXCR4, and GOF-5,

researchers were able to inhibit LPS-induced TNF-a production and activation of
monocytes (Triantafilou et al. 2001; Triantafilou et a/. 2001 a). Thus, it appears
probable that there are a host of several membrane proteins that form an LPS
receptor domain.
MD-2

1\110-2 is a small secreted glycoprotein that lacks a transmembrane
domain, which acts as an extracellular adaptor protein in conjunction with TLR4,
and is essential for LPS signaling to occur (Shimazu et al., 1999) (Figure 4). The
physiologic necessity for MO-2 in the LPS response has been demonstrated
using a mutant form of mice which lack MO-2 (Nagai et al., 2002). Bone marrowderived macrophages from mice lacking MO-2 were unable to produce
inflammatory cytokines upon stimulation by LPS. These findings were reinforced
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in a study using a mutant cell line derived from Chinese hamster fibroblasts in
which there was normal cell surface expression of TLR4, but also a point
mutation in a conserved region of MD-2 (C95Y) that showed no response to LPS.
Additionally, in another study, wild-type MD-2 was able to restore the LPS
response in cells expressing TLR4 but lacking MD-2 (Schromm et al., 2001;
Visintin et al., 2001).
It has also been demonstrated that MD-2 is involved in regulating the
intracellular positioning of TLR4 (Nagai et aI., 2002). In embryonic fibroblasts
lacking MD-2, TLR4 predominantly accumulated within the Golgi apparatus and
failed to be correctly transported to the cell surface.
Thus it appears that MD-2 plays a pivotal role, having both a regulatory
activity for the cellular distribution of TLR4, and also involved in LPS recognition
and signal transduction through TLR4. In fact, LPS binds to MD-2, which then
associates with TLR4 by means of the extracellular LRRs, inducing NF-KB
activation and signaling via TLR4 (Visintin et al., 2003). It therefore seems
plausible that the functional integrity of the "LPS Receptor Complex" depends on
the cell surface expression of a variety of host proteins and the concept of a
"monogamous" relationship between LPS and TLR4 may in reality be an
oversimplification.

LPS Signaling through TLR4
My088-0ependent Signaling Pathway

Since the TLRs share sequence homology with the IL-1 receptor family,
LPS sjgnaling is thought to occur in a similar manner. These two pathways, are
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in fact, mediated by common components. The principle signaling pathway
activated by TLR4 in response to LPS occurs through sequential recruitment of
adapter proteins. These adapters include myeloid differentiation factor 88
(MyD88), a family of IL-1 receptor-associated kinases (IRAK), and TNF receptoractivated factor 6 (TRAF6) (Muzio et al., 1996; Burns et al., 1998; Medzhitov et
al., 1998). The cytoplasmic adapter MyD88, which is also a Toll-like molecule, is

normally bound to the intracellular "TIR" domain of TLR4 by TolllToll interactions.
Upon stimulation, MyD88 recruits IRAK-4 to the receptor complex which then
facilitates the phosphorylation of IRAK-1. Activated IRAK-1

subsequently

dissociates from the receptor complex and interacts with TRAF6, which results in
the activation of two distinct signaling pathways, NF-KB or c-jun N-terminal
kinase (JNK), both of which are involved in the activation of numerous
inflammatory genes and expression of inflammatory cytokines (Figure 5) (Cao et
al. , 1996; Muzio et al., 1997; Burns et aI., 1998; Medzhitov et al., 1998. Muzio et
al.,1998).

Additionally, gene targeting studies have shown that NF-KB has a

critical role in osteoclast differentiation (Franzoso et aI., 1997; lotsova et aI.,
1997).
Figure 5. Schematic diagram of the My088dependent and My088-independent pathways.
Refer to text for explanations.
Image obtained from :
www.rsc.org/delivery/ ArticleLinking/Display
H ...
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My088-lndependent Signaling Pathway
Although MyD88 is an absolute requirement for the production of
inflammatory cytokines, MyD88-deficient macrophages showed a delayed
activation of the NF-KB and JNK pathways in response to LPS stimulation
compared with macrophages from wild-type mice (Kawai et al., 1999).

This

indicates that even though LPS-induced inflammatory cytokine production is
entirely dependent on the MyD88 pathway, there also exists a MyD88independent component in LPS-TLR4 signaling.
LPS stimulation of MyD88-deficient macrophages leads to activation of the
transcription factor IFN-regulatory factor 3 (IRF-3), which subsequently induces
IFN-~.

IFN-~

then activates Stat1, which results in the expression of several IFN-

inducible genes (Figure 5) (Kawai et al., 2001; Doyle et al., 2002; Toshchakov et

al., 2002).

Regulation of Osteoclast Formation
Osteoclasts are large, multinucleated specialized giant cells responsible
for bone resorption that arise from a hematopoietic stem cell lineage of
monocytes and macrophages (Suda et al., 1992). Osteoclastic bone resorption
consists of multiple steps and studies have identified several key elements
thought to be important for osteoclast differentiation (osteoclastogenesis) and
activation (Teitelbaum and Ross, 2003).

These include macrophage-colony

stimulating factor (M-CSF), receptor activator of nuclear factor kappa B ligand
(RANKL), tumor necrosis factor-a (TNF-a), interferons (IFNs), and interleukins
(I Ls). Of these factors, M-CSF and RANKL are thought to play an essential role
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The in vivo significance of the RANKL-RANK signaling pathway in
regulating skeletal development and bone remodeling has been demonstrated by
a series of gene disruption studies using a mouse model (Teitelbaum and Ross,
2003).

Mice lacking either RANKL or RANK developed severe osteopetrosis,

with total occlusion of the bone marrow space within endosteal bone, due to
failure to form osteoclasts (Dougall et al.. 1999; Kong et al., 1999). Conversely,
the targeted disruption of OPG led to the development of early onset
osteoporosis due to increased numbers of activated osteoclasts (Bucay et al.,
1998).

RANK Signaling in Osteoclast Differentiation

RANK signaling is mediated through specific adapter molecules called
TNFR-associated factors (TRAFs) (Rho et al., 2004). Although the TRAF family
contains six members (TRAFs 1, 2, 3, 4. 5. and 6), and RANK can directly
interact with five of them (TRAFs 1. 2, 3, 5, and 6), only TRAF-6 appears to be
critical for osteoclast differentiation (Galibert et al., 1998; Darnay et a/., 1999).
RANKL stimulation facilitates the recruitment of TRAF6 to one or more of the
three binding motifs in the cytoplasmic domain of the RANK receptor which then
activates several downstream signaling cascades. Six key signaling pathways
have been identified in osteoclasts: nuclear factor of activated T-cell (NFAT) c1.
nuclear factor kappa B (NF-kB), Aktlprotein kinase B (PKB). Jun N-terminal
kinase (JNK), extracellular signal-regulated kinase (ERK) and p38. all of which
promote survival and differentiation (Figure 7) (Boyle et a/., 2003).
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Figure 7. Schematic representation of RANK signaling in osteoclast differentiation. Modified
from Feng , 2005 .

However, recent findings support the notion that LPS and some
inflammatory cytokines such as TNF-a and IL-1 may also be directly involved in
osteoclast

differentiation

and

activation

through

a

mechanism

partially

independent from that of the RANKL-RANK interaction (Jimi et ai, 1999; Suda et
al., 2002; Kobayashi et al., 2000; Jiang et al., 2006). The intracellular signaling

cascade of TLR4 is similar to that of IL-1 receptors and both of these receptors
have been shown to use TRAF6 as a common signaling adapter molecule
(Kobayashi et al., 2004). When osteoclast precursors were stimulated with both
LPS and RANKL, LPS-induced osteoclast formation was observed even in the
presence of OPG and IL-1 receptor antagonists (Suda et al., 2002; Jiang et al.,
2006). Osteoclast formation was also stimulated by LPS in preosteoclast cells
from mice missing tumor necrosis factor (TNF)-receptor-I or TNF-receptor-II
(Suda et al., 2002). These results suggest that LPS stimulates osteoclast
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formation independent of RANKL, IL-1, or TNF-alpha action, and have opened
new areas for exploring the molecular mechanisms of osteoclast differentiation.
They also constitute a potential therapeutic target for the modulation of excessive
osteoclast differentiation in pathogenic bone and oral diseases (Figure 8).
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/\
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l
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Figure 8. Schematic representation of osteoclast activation by RANKL, IL-l, and LPS through
their respective receptors. TRAF6 appears to act as a common signaling adapter molecule
involved in all three pathways. Modified from Katagiri and Takahashi 2002 .

NFATc1

NFATc1 is the most strongly induced transcription factor gene mediated
by RANKL stimulation. It has also been shown to be a key regulator of
osteoclastogenesis and plays a critical role in the terminal differentiation of
osteoclasts (Takayanagi et al., 2002).

RANKL-induced recruitment of TRAF6

results in the induction of intracellular calcium, which leads to the activation of
calcineurin

(Takayanagi

et

al.,

2002).

Activated

calcineurin

then
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dephosphorylates and activates NFAT1, allowing it to translocate to the nucleus
to form a ternary complex with c-Fos and c-Jun to stimulate NFATc1 gene
expression (Figure 7) (Ikeda et al., 2004).

At the final stage of osteoclast

differentiation, NFATc1 works in conjunction with Fos and Jun proteins to
stimulate osteoclast-specific genes such as tartrate-resistant acid phosphatase
(TRAP), calcitonin receptor, and cathepsin K (Ikeda et al., 2004).

Thus it

appears that the NFATc1 pathway is a crucial component of osteoclast
differentiation, and inhibition of this pathway may provide yet another potential
therapeutic approach for the treatment of bone diseases.

RNA Interference (RNAi)
RNA interference (RNAi) is a process in which specific sequences of small
pieces of double-stranded RNA (small interfering RNA [siRNA]) are used to
silence the expression level of sequence-homologous genes (Dykxhoorn and
Lieberman, 2005). It now appears that it is an evolutionary conserved process in
plants and invertebrates that may have originated as a cellular defense, whose
natural function is to protect cells against viral infection and other potentially
harmful

genetic

elements

that

make

double-stranded

RNA

(dsRNA)

intermediates (Lee and Ambros, 2001).
RNAi is arguably one of the most significant and promising technological
advances in modern scientific history.

Science magazine hailed it as the

"Breakthrough of the Year" in 2002, and in 2006 the Nobel Prize in Physiology or
Medicine was awarded to those responsible for its discovery. This phenomenon
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was first discovered in plants when researchers were trying to genetically
engineer a more intensely colored petunia using a transcribed sense transgene
that encoded an enzyme for the synthesis of purple pigment, but unexpectedly
found suppression of the homologous endogenous gene (Napoli et al., 1990).
This was termed post-transcriptional gene silencing (PTGS).

However, it was

Andrew Fire, Craig Mello, and colleagues who made the discovery that
sequence-specific dsRNA was the source of gene silencing in the nematode
worm-Caenorhabditis elegans-and termed this RNA interference (Fire et al.,
1998). In their experiment, they separately introduced sense and antisense RNA
to a particular gene into the cells of the worm and found, at best, the antisense
RNA caused a modest reduction in gene expression. Yet, when both molecules
were allowed to hybridize and then injected, there was a profound and specific
interference.
Additional studies revealed that when long dsRNA molecules are
introduced in plants and invertebrates, they are internally processed by an
enzyme called Dicer into small dsRNAs, 21 to 23 nucleotides (nt) in length,
referred to as siRNA (Hammond et al., 2000, Zamore et al., 2000; Bernstein et
al., 2001). However, in mammals, exposure to dsRNAs greater than 30 base
pairs provokes a systemic and nonspecific inhibition of mRNA translation as a
result of activation of the antiviral interferon response (McManus and Sharp,
2002). It was thus a significant breakthrough when, in 2001, it was demonstrated
that chemically synthesized short dsRNA molecules of 21-22 nt in lengthsiRNA-could be used to directly trigger RNAi in mammalian cells without
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initiating the interferon response (Elbashir et al., 2001). Since then, RNAi has
revolutionized biological research as a new and powerful tool for the study gene
function by suppressing its expression, and attracted the attention of academic
researchers, the medical community, and the pharmaceutical industry for its
potential therapeutic applications in the treatment of disease.

Mechanism of RNA Interference

RNAi is triggered when the host cell encounters long dsRNAs produced by
viral sources or exogenously administered synthetic siRNA precursors (Lee and
Ambros, 2001). Once in the cytoplasm, these RNA molecules are processed by
the ribonuclease III-like enzyme known as Dicer, to generate RNA duplexes 2122 nt in length (siRNA) with a 2- to 3-nucleotide unpaired overhang at each end
(Elbashir et al., 2001 a). These siRNA fragments are then incorporated into large
protein complex, known as the RNA-induced silencing complex (RiSe), by which
the double-stranded siRNA is unwound into single-stranded siRNA (Nykanen et

al., 2001).

The antisense strand of the duplex siRNA then guides the RiSe

complex to the homologous mRNA.

Once bound to its target through simple

Watson and erick base paring, RiSe is activated by ATP and cleaves the mRNA
at a single site approximately in the middle of the region paired with the
antisense siRNA, resulting in silencing of the target gene (Elbashir et al., 2001a;
Martinez et al' 2002). The cleavage products are degraded and released from
J

the siRNA-RiSe complex, freeing it to search for and further diminish the
available pool of target mRNA (Figure 9) (Meister and Tuschl, 2004).
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Figure 9. Schematic representation of the RNAi mechanism. RNAi is induced when the host cell
encounters long dsRNA from viruses or exogenously administered synthetic siRNA. Once in the
cytoplasm, they undergo processing by an enzyme called Dicer. This results in the formation of a
dsRNA between 21-23 nucleotides in length. This siRNA binds with several cellular proteins
forming a complex referred to as RNA interfering silencing complex (RISe), which guides the
siRNA to its homologous target mRNA. Once bound to its target through simple Watson and
erick base paring, RISe then cleaves the mRNA approximately in the middle of the region paired
with the antisense siRNA, and effectively leads to further degradation of the mRNA.
Image obtained from : http://arunbt.googlepages.com/

Design of Effective siRNA probes
Functional RNAi is dependent upon the sequence specificity of the siRNA
probe to the target gene of interest. Thus, design of the siRNA sequence is
crucial for effective gene silencing.

Currently, siRNA design is based on an

understanding of RNAi biochemistry, and several groups have developed
empirical guidelines for effective siRNAs design. These guidelines recommend

33

the use of siRNAs that are 21 nt long with a 3' overhang of 2 nucleotides. The
siRNA should be complimentary to the target mRNA at a location 75-100 bases
downstream of the start codon of the gene of interest and the target site should
have a GC content less than 50 percent. Finally, a BLAST-search of the target
site should be carried out to the appropriate genome database to ensure that
only one gene is being targeted and 3-4 siRNA should be tested for each gene to
minimize possible nonspecific off-target effects (Elbashir et al. 2001 b, Khvorova

et al., 2003; Reynolds et al., 2004). At this time, the siRNAs of many gene
products of interest have been synthesized and act as readymade Dicer
products.

Delivery Strategies of siRNA
The delivery of nucleic acids into mammalian cells is called transfection.
Functional RNAi requires effective transfection procedures without side-effects or
cytotoxicity. Successful introduction of siRNA into cells of interest have been
demonstrated using either plasmid or viral vectors (Brummelkamp et al., 2002;
Paddison et al., 2002). Synthetic siRNAs delivered to cells in culture by
electroporation or the use of lipophilic agents have also been used to
successfully silence target gene expression (Elbashir et al., 2002; Mellitzer et al.,
2002). There are several commercially available transfection kits that can be
used for the application of RNAi. Lipofectamine 2000 and Oligofectamine
(Invitrogen) are two that are routinely used for siRNA delivery.
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Therapeutic Potential of RNAi

Given that most diseases are genetic-based and the genetic etiology of
many disorders has been defined, the therapeutic promises of RNAi are
potentially enormous. It seems evident that RNAi is not only a powerful research
tool for studying gene function, but that it is also a fast and inexpensive method
to selectively silence a gene product in complex biological systems. The
sequence-specific gene inhibition by siRNA has shown genuine therapeutic
potential and opened new horizons in the areas of cancer research, HIV
treatment, genetic disorders, and pharmaceutical drug development (Jacque et
al., 2002; Brummelkamp et al., 2003; Dorsett and Tuschl, 2004; Whelan, 2005).
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Aim of Study
Thus the objective of this study was to utilize RNAi using specific siRNA to
silence TLR4 or NFATc1 expression in monocytes and osteoclast cells in order
to modulate the effects of LPS stimulation, and to provide a potential therapeutic
approach in the field of endodontic research. The specific aims for this study are:

Specific Aim 1:

To examine the efficiency of siRNA transfection in

monocytes and osteoclasts.

Specific Aim 2: To examine the expression of TLR4 and NFATc1 levels in
osteoclast cells transfected with specific siRNA

Specific Aim 3:

To examine the biological effect of the suppression of

TLR4 and NFATc1 with effective siRNA. The transfected and control cells
will be stimulated with LPS. The production of cytokines will be examined
with ELISA and osteoclast formation will be quantitatively analyzed.
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Material and Methods

Preparation of Osteoclasts

Osteoclast-like cells (OCl) were differentiated from RAW 264.7 cells, a
mouse hematopoietic cell line (American Type Culture collection, Rockville, MD).
For morphological examination, RAW 264.7 cells were plated at a density of
40,000 cells/well in 24 well plates in alpha modified Eagle medium with 10% fetal
bovine serum (Invitrogen, Carlsbad, California).

The cells were incubated at

37°C in a humidified atmosphere containing 5% CO 2 .

TRAP Assay

Tartrate resistant acid phosphatase (TRAP) is a marker enzyme specific
for osteoclasts. At 96 h of culture, cells were fixed with 2% paraformaldehyde,
washed with phosphate buffered saline, and treated for 20 minutes with 0.2%
Triton X-100 solution to permeabilize cell membranes. Cytochemical staining of
tartrate-resistant acid phosphatase (TRAP)-positive cells was performed as
described previously (Holliday et a/., 2003). TRAP-positive cells appeared dark
red. Only TRAP-positive cells with more than 3 nuclei were counted. The values
are expressed as means ± SE of triplicate cultures.
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RNA Extraction, Quantification, and Reverse Transcription
Total RNA was extracted using TRIZOL reagent (Invitrogen) and
phenol/choloroform according to manufacturer's instructions. RNA was dissolved
in Tris-EDTA (TE), PH 7.4 and the concentration of RNA was determined by
measuring the spectrophotometric absorbance at 260 nm. The concentration of
extracted RNA was 0.5 I-Ig/I-II-1 I-Ig/I-II. RNA was treated with DNAse I (Invitrogen)
for 15 minutes followed by DNase I inactivation with 25 mM EDTA at 65°C to
remove genomic DNA contamination. Reverse transcription was carried out in a
20 1-11 volume containing about 3 I-Ig of RNA, 11-11 of 50 ng/I-II random hexamers
and 1 IJI annealing buffer, 10 1-11 2X first-strand reaction mix and 2 1-11 superscript
III/RNase OUT enzyme mix (Invitrogen) at 25°C for 10 minutes and then at 50°C
for 50 minutes.

Real-time peR
Taqman real-time PCR was performed from 1 1-11 of cDNA using TaqMan
Universal PCR Master Mix (Applied Biosystems, Foster City, CA) with 100-nM
primers and a 50-nM probe. The Taqman Real-time RT-PCR was performed on
a Taqman ABI 7500 sequence Detection System (Applied Biosystems).
Unlabeled specific primers and the TaqMan MGB probes (6-FAM dye-labeled)
for detecting the mouse TRAP gene (Assay 10: Mm00475698 m1); calcitonin
receptor gene (Assay 10: Mm00432271 m1) and cathepsin K gene (Assay 10:
Mm00484036 m1) were used. A Taqman eukaryotic 18S endogenous control kit
was used for housekeeping gene control. Cycling conditions were: After an initial

38

hold of 2 minutes at 50°C and 10 minutes at 95°C, the samples were cycled 40
times at 95°C for 15 seconds and 60°C for 1 minute. Each sample was assayed
in triplicate.
Traditional PCR used to analyze the amount of PCR product at the end of
the reaction does not truly represent the initial amount of starting material
whereas real-time PCR monitors the amount of amplicon in the reaction as it is
produced during each PCR cycle.

As a result, real-time PCR methodology

provides fast, precise, and accurate results by monitoring the amplification of
products during the reaction and allows quantification of rare transcripts and
small changes in gene expression. The Taqman technique is most widely used
for real-time PCR detection techniques. It uses the 5'-3' exonuclease activity of
Taq DNA polymerase to cleave a dual-labeled probe annealed to the target
sequence during PCR amplification. The probe, a sequence complementary to
the mRNA located between the forward and reverse primers, contains both a
fluorescent reporter dye at the 5'-end and a quencher dye at the 3'-end. The
fluorescent emission activity of the reporter dye is neutralized by a quenching
dye when the TaqMan probe is hybridized to its target sequence. During PCR
amplification, Taq DNA polymerase cleaves the TaqMan probe into fragments
through its 5'-3' endonucleolytic activity. Thus the reporter dye is separated from
the quenching dye, resulting in an increase in fluorescence that is directly
proportional to the amplification of the molecule.

Applied Biosystem has

commercially available fluorescence-labeled primers and probes for mouse
osteoclast-specific genes and endogenous control gene 185 ribosomal RNA.
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Real-time PCR is currently considered the gold standard for quantitative
measurement of mRNA, having both high sensitivity and specificity.

Statistical Analysis of Ct Comparative Gene Expression
The comparative Ct method was applied to determine comparative
expression levels between samples relative to control gene expression.

To

examine regulation by NFATc1-specific or TLR4-specific siRNA, the amplification
threshold cycle value (Ct) from each treated sample was subtracted from the
control-treated sample cycle values (ACt=Ct control-Ct treated).

The ratio was

obtained by calculating the values obtained for gene of interest and the housekeeping gene 18S rRNA. The fold change of the test gene was determined as
2(L'lCI gene- L'I ct 185).

Data are expressed as mean values ± SEM.

Statistical significance of

differences was determined by one way ANOVA and followed by posthoc test
(Fisher's protected least significant difference (PLSD).

Differences were

considered statistically significant at P < 0.05.
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siRNA Transfection

TLR4 or NFATc1 were silenced by using TLR4 or NFATc1 SMARTPOOL
small interfering RNA (siRNA) reagent (Dharm), respectively.

For osteoclast examination, RANKL-stimulated RAW 264.7 cells on glass
coverslips in 24-well plates for first 24 h were either not transfected or transfected
using 1.5 U control or effective siRNA and 1.5 U fluorescent double-stranded
RNA (Dharham) combined with 2

1-11

lipofectamine 2000 (Invitrogen) in Opti-MEM

media supplemented. Six hours after transfection, the media was replaced by
aMEM with fetal bovine serum (FBS) and 100 ng/ml LPS. No antibiotics were
used. The cells were incubated for 30 h at 3rC in a CO 2 incubator for additional
4 days after which they were fixed in 2% paraformaldehyde. The nuclei were
then counterstained with a DAPI stain, which binds the nucleotides, in order to
visualize the relative location of the siRNA. Only cells with uptake of the
fluorescent oligomer (FITC) by fluorescent microscopy were identified as having
the control siRNA.

For assessment of cytokine expression, RAW264.7 cells were plated on
24-well plates with DMEM and 10% FCS at density 40,000/well for 24 h. Cells
were then either not transfected or transfected using 1.5 U control or
experimental siRNA and 1.5 U fluorescent oligomer combined with 2
lipofectamine 2000.

1-11

Six hours after transfection, the media was replaced by

DMEM with FBS. The cells were incubated at 3rC in a CO 2 incubator for an
additional 3 days. During the last 24 h of culture, cells were stimulated with 100
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ng/ml LPS. The medium were collected and stored in -70°C for ELISA analysis.
RNA was extracted for real-time PCR assay.

ELISA

Concentrations of IL-1, IL-6, and TNFa in culture supernatants were
determined by ELISA in triplicate with commercial ELISA Duo systems (R&D
systems), according to the respective manufacturer's instructions.

For each

sample and assay, the mean of the triplicate measurement were calculated.

Immunostaining and Microscopy

Marrow osteoclasts or RAW 264.7-derived osteoclast-like cells were fixed
in 2% formaldehyde in PBS on ice for 20 minutes. Osteoclasts were detergentpermeabilized with 0.2% Triton X-100 in PBS for 10 minutes, washed, and
blocked in PBS with 2% bovine serum albumin (BSA) for 2 h. The cells were
stained with rhodamine-phalloidin or antibodies recognizing TLR4, NFATc1 at a
dilution of 1: 100 in PBS. Secondary antibodies were diluted according to the
manufacturer's instructions.
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Results

Evaluation of siRNA Transfection in Monocytes

Traditionally, it is difficult to manipulate gene expression in monocytes and
especially osteoclasts, because they are terminally differentiated cells. Monocyte
cells were transfected with a fluorescently labeled control siRNA using a
commercially

available

microscopy 72

lipfectamine

kit

and

hours post transfection

visualized

(Figure

9).

by

fluorescence

The nuclei were

counterstained with a DAPI stain, which binds the nucleotides in order to
visualize the relative location of the siRNA (Figure 10).

Figure 9. Monocytes transfected with
control fluorescent-labeled siRNA and
visualized by fluorescence microscopy.

Figure 10. Monocyte nuclei stained with
DAPI.

When the two images above are superimposed, we see the red dots around the
nuclei, which indicates that the siRNA are delivered into the cytoplasm with high
efficency (Figure 11).
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Figure 11. SiRNA are delivered mainly to the cytoplasm with
high efficency.

Evaluation of siRNA Transfection in Osteoclast-like cells
Similarly, we used osteoclast-like cells that were differentiated using LPS
or RANKL and tranfected them with fluorescent-labeled siRNA (Figure 12) and
the nuclei were stained with DAPI (Figure 13).

Figure 12. Osteoclast-like cells
transfected with fluorescent-labeled
siRNA.

Figure 13. Osteoclast nuclei stained with
DAPI.
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When the two images above are superimposed, we see that osteoclasts are
multinucleated (as indicated by the blue dots) and the fluorescent-labeled siRNA
are highly concentrated in the peripheral cytoplasm around the nucleus.
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Figure 14. SiRNA are delivered mainly to the cytoplasm of
osteoclasts with high efficiency.

When we stained with TRAP, which is a purple stain and marker for osteoclast
identification, we see TRAP+ cells that are phenotypically identical to
untransfected osteoclasts (Figure 15).

Figure 15. Osteoclasts transfected with siRNA appear
phenotypically identical to untransfected osteoclasts.
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Silencing NFATc1 Expression in Osteoclasts with siRNA

In the next step, we examined the efficacy of siRNA in silencing NFATc1
protein expression. In the control group, osteoclast cells were transfected with
control siRNA and immunocytologically stained with anti-NFATc1 antibody. This
method locates NFATc1 protein expression inside the cell. We observed intense
nuclear accumulation of NFATc1 protein in osteoclasts which was to be
expected, as NFATc1 is a transcription factor and therefore should be located in
the nucleus (Figure 16). In the experimental group, osteoclasts were transfected
with NFATc1-specific siRNA and similarly stained witl, anti-NFATc1 antibody.
We observed a significant reduction of NFATc1 protein expression in the nucleus
as compared to the control (Figure 17).

Figure 16. Osteoclasts transfected with
control siRNA show intense nuclear
accumulation of NFATc1 protein (arrows).

Figure 17. Osteoclasts transfected with
NFATc1 show a significant reduction of
NFA Tc1 protein in the nucleus (arrows).
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When the nuclei were counterstained with DAPI and the images were
superimposed, we can better appreciate that the nuclei are still present in both
groups, even though there was reduced NFATc1 protein expression in the
experimental group (Figure 18).
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Control siRNA

NFATc1 siRNA

Figure 18. Nuclear staining with DAPI reveals that nuclei are still present in both the
control and experimental groups.

This indicates that we were able to partially silence the expression of NFAT c1 in
osteoclasts using NFATc1-specific siRNA.

Silencing TLR4 Expression in Osteoclasts with siRNA
Similarly, we examined the efficacy of siRNA in silencing TLR4 protein
expression. In the control group, osteoclast cells were transfected with control
siRNA and immunocytologically stained with anti-TLR4 antibody (Figure 19). In
the experimental group, osteoclasts were transfected with TLR4-specific siRNA
and also stained with anti-TLR4 antibody. We observed a significant reduction in
TLR4 expression on the cell surface as compared to the control (Figure 20).
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Figure 19. Osteoclasts transfected with
control siRNA and stained with AntiTLR4 antibody.

Figure 20. Osteoclasts transfected with
TLR4-specific siRNA and stained with
Anti-TLR4 antibody.

When the nuclei were counterstained with

DAPI and the two images

superimposed, we can see that the nuclei are unaffected in both groups, even
though there is reduced TLR4 protein expression in the experimental group
(Figure 21).

Control siRNA

TLR4siRNA

Figure 21. Nuclear staining with DAPI reveals that nuclei are still present in both the control
and experimental groups.

This indicates that we were also able to partially silence the expression of TLR4
in osteoclasts using TLR4 specific siRNA.
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Biological Effects of Silencing NFATc1 or TLR4 Expression in Monocytes
Since monocytes are the predominant producers of cytokines in response
to LPS stimulation, we then examined what effect silencing NFATc1 or TLR4
expression would have on TNF-a, IL-6, and IL-1 production.

Monocytes were

transfected with either NFATc1-specific, TLR4-specific, or control siRNA and the
cells were stimulated with LPS.

Media was collected after 24 hours and

analyzed for cytokine production using ELISA. Results are shown in Table 1.
Analysis of Variance revealed cells in both the NFATc1-specific and TLR4specific siRNA groups showed a statistically significant resistance to LPS
stimulation as indicated by the down regulated TNF-a and IL-6 levels compared
with that in the control siRNA group (p<O.05) (Figure 22).

There was no

statistical significance between the NFATc1-specific or TLR4-specific siRNA
groups for TNF-a or IL-6 production. There also was no significant difference
between or among the control, NFAT-c1, or TLR4 siRNA groups when analyzed
for IL-1 production.
Monocyte Cytokine Production
IL-6 ELISA
NOLPS
Not detectable

TNF-alpha ELISA
Not detecatble

IL-1 alpha ELISA
Not detectable

(measured in ng/ml)
LPS+control siRNA
9.52 +/-2.05

LPS + TLR4 siRNA
*3.48 +/-0.78

LPS +NFATc1 siRNA
*5.11 +/-0.98

(measured in ng/ml)
23.49 +1-0.98

*15.17 +/-1.01

*18.31 +/-1.43

(measured in pg/ml)
30.7 +/-3.2

25.7 +/-3.8

32.7 +/-2.5

Table 1. Biological effects of silencing NFATc1 or TLR4 on monocyte cytokine production
*denotes statistical Significance relative to control, P<O.OS. (Data obtained from an
average of 3 trials)
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Treatment Groups
Figure 22. Inhibition of cytokine release in monocytes mediated by
siRNA. * denotes statistical significance relative to control, P<O.05.

Biological Effects of Silencing NFATc1 or TLR4 Expression on Osteoclast
Formation

Monocytes were stimulated with RANKL for 24 hours and then transfected
with either NFATc1-specific, TLR4-specific, or control siRNA. Cells were then
stimulated with LPS for an additional 72 hours.

TRAP+ cells with more than

three nuclei were counted. Results are shown in Table 2.

Number of Osteoclasts Formed
IControl siRNA
356 +/-25

I

I
I

TLR4 siRNA
*234 +/-58

I
I

NFATc1 siRNA I
*152 +/-39 I

Table 2. Biological effects of silencing NFA Tc1 or TLR4 on osteoclast
formation. *denotes statistical significance relative to control, P<O.05.
(Data obtained from an average of 3 trials)
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Analysis of Variance revealed a statistically significant fewer number of
osteoclasts formed in cultures treated with NFATc1 or TLR4-specific siRNA as
compared with that in the control siRNA group (P<O.05) (Figures 23 and 24).
There was no statistical significance between the NFATc1 or TLR4-specific
siRNA groups with respect to the number of osteoclasts formed.
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Figure 23. Inhibtion of osteoclast formation mediated by siRNA. *denotes statistical
significance relative to control, P<0.05.

Cultures transfected with control siRNA
Figure 24.

Cultures transfected with either NFATc1 or
TLR4 siRNA.
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Biological Effects of Silencing NFATc1 or TLR4 Expression on OsteoclastSpecific Gene Expression

Osteoclast-like cells were differentiated using LPS or RANKL and
tranfected with either NFATc1-specific, TLR4-specific, or control siRNA.

Cells

were then stimulated with LPS for an additional 72 hours. RNA was extracted
and reverse transcribed into cDNA and Real time PCR (RT PCR) was performed
to determine comparative mRNA expression levels of cathepsin K, tartrateresistant acid phosphatase (TRAP), IL-6, and TNF-a relative to control gene
expression. The relative expression fold change determined from the application
curve of RT PCR revealed a statistically significant decrease of cathepsin K,
TRAP, IL-6, and TNF-a mRNA levels in osteoclasts treated with NFATc1 or
TLR4-specific siRNA as compared with that in the control siRNA group (P<O.05)
(Figure 25). There was no statistical significance between the NFATc1 or TLR4specific siRNA groups with respect to mRNA expression levels.
Osteoclast mRNA Expression
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Figure 25. Inhibition of osteoclast mRNA expression mediated by siRNA. *denotes statistical
significance relative to control, P<O.05.

52

Biogical Effects of Silencing NFATc1 or TLR4 Expression on Osteoclast
TNF-a Production

Osteoclast-like cells were differentiated using LPS or RANKL and
tranfected with either NFATc1-specific, TLR4-specific, or control siRNA. Cells
were then stimulated with LPS for an additional 72 hours. Media was collected
and analyzed for TNF-a cytokine production using ELISA. Results are shown in
Table 3.

Osteoclast TNF-alpha Production
Control siRNA

TLR4siRNA

3.8 ng/ml +1-0.29

*2.6 ng/ml +1-0.32

NFATc1 siRNA
*1.88 ng/ml +/-0.14

Table 3. Biological effects of silencing NFATc1 or TLR4 on osteoclast TNF-a production.
*denotes statistical significance relative to control, P<O.05. (Data obtained from an average

of 3 trials)

Analysis of Variance revealed osteoclasts in both the NFATc1-specific and
TLR4-specific siRNA groups showed a statistically significant resistance to LPS
stimulation as indicated by the reduced TNF-a production compared with that in
the control siRNA group (p<O.05) (Figure 26).

There was no statistical

significance between the NFATc1-specific or TLR4-specific siRNA groups for
TNF-a production.
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Figure 26. Inhibition of TNF-a production in osteoclasts mediated by siRNA. *denotes
statistical significance relative to control, P<0.05.
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Discussion
RNA interference is a conserved biologic response by which dsRNA
induces the sequence-specific degradation of complementary mRNA, thereby
silencing target gene expression. It has rapidly become the method of choice for
studies of gene function and gene silencing experiments.

We chose to

independently suppress the expression of two different proteins involved in the
mechanism of cytokine production and osteoclast formation. Toll-like receptors
are a newly discovered class of trans-membrane receptors found on the surface
of immune cells, whose activation has been shown to be critical for the initiation
of inflammatory reactions induced by bacterial byproducts.

TLR4 is the

established receptor for LPS, which is an integral component of the cell wall of
gram-negative bacteria found in the root canals of infected teeth.

The

relationship between LPS and periapical bone resorption has been well
documented in endodontic literature. Previous studies have demonstrated the
mechanisms by which LPS stimulates osteoblasts and surrounding cells to
secrete pro-inflammatory cytokines such as TNF-a and IL-6 that are responsible
for bone resorptive activity (Nair, 1996). More recent findings have shown that
LPS can directly stimulate osteoblasts through NF-KB activation of target genes
to express RANKL, which results in the induction of osteoclast formation (Kikuchi
et al., 2001). Our group was able to demonstrate that LPS can directly induce

monocytes to differentiate into mature osteoclasts through a shared mechanism,
yet independent from the RANK-RANKL interaction (Jiang et al., 2006). NFATc1
is the most strongly induced transcription factor gene mediated by RANKL
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stimulation whose presence has been shown to be required during the final stage
of osteoclastogenesis.
It has been previously demonstrated that antisense sequence targeting of
TLR4 inhibited TLR4 expression and reduced TNF-a release when RAW 264.7
cells were stimulated by LPS (Li et al., 2004). Our ability to successfully transfect
and silence TLR4 and NFATc1 gene expression with specific siRNA in
monocytes resulted in a significant reduction of LPS-induced TNF-a and IL-6
production and fewer numbers of mature osteoclasts formed. We did not observe
a difference in IL-1 production, but that may be due to the fact that monocytes
produce very low levels of IL-1 to begin with, as was demonstrated in the control
group. We also showed that successful transfection of osteoclasts with TLR4 or
NFATc1-specific siRNA resulted in a significant reduction of osteoclast specific
gene expression and lower levels of TNF-a production.

Further studies using

RNAi in animal models need to be conducted in order to observe the therapeutic
relevance in treatment of endodontic disease.
There are two reasons that can account for the fact that we did not obtain
100% silencing of the gene products observed: 1) This technique only blocks the
expression of newly transcribed mRNA, and the observed levels may be due to
residual proteins expressed by the cells prior to siRNA transfection and 2)
background from mRNA or protein present in cells that were not successfully
transfected will make the knockdown appear less effective than it actually is
(Zhou et al., 2006). Nonetheless, this demonstrates the potential that RNAi may
have as a novel therapeutic strategy in treating endodontic disease.
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Several other approaches have been used in the past which utilize
sequence homology for the targeted inhibition of gene expression.

These

include Homologous Recombination, Antisense Vectors, and catalytic DNA
molecules (DNAzymes) (Capecchi, 1989; Scherer and Rossi, 2003). However,
due to their limited cross-species application, none show to be as promising as
RNAi (Opalinska and Gewirtz, 2002).
Currently, RNAi is most commonly used as a rapid and accurate tool for
identification of gene function. Many researchers have employed this technology
to elucidate the roles of individual genes in regulating cell growth, differentiation,
and survival in a broad range of cell lines (Klampfer et al., 2004; Yin et al., 2004).
Other groups have deployed RNAi for the identification of potential drug targets
by determining gene function and linking it to specific diseases (Nencioni et al.,
2004). This process is known as drug target discovery. These types of studies
represent a powerful approach for the identification of new drug target sites by
identifying a potential therapeutic target and verifying the desired effect of that
target upon regulation. RNAi has also been used to dissect cellular signal
transduction pathways. Cells treated with siRNA targeting a given gene can then
be monitored using a microarray for the expression of other genes. Sequential
targeting of various genes with siRNA makes it possible to identify genes that are
associated with the target and to locate the position of each gene in a given
pathway. This technology has been successfully used in determining gene
function in the transforming growth factor beta

(TGF-~)

pathway, mitogenic
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signaling pathway in osteoblasts, and insulin signaling (Levy and Hill, 2005;
Miguel et al., 2005; Shyu et al., 2005).
However, the greatest promise for RNAi may be in the field of clinical
medicine, and its potential for therapy against a broad range of diseases.
Preliminary studies using siRNA to specifically target the HIV structural proteins
Gag and Env, the regulatory proteins Tat and Rev, the two accessory proteins
Nef and Vif, the Pol enzymes, or the viral RNA sequences in the long terminal
repeat (LTR) domain have been shown to potently inhibit HIV-1 replication in
human T cell lines (Jacque et al., 2002; Novina et al., 2002).

In addition to

targeting of the viral RNA, others have sought to inhbit viral replication using
RNAi by silencing host cell receptors such as CD4, CXCR4, and CCR5 which are
essential for attachment and subsequent entry of the HIV-1 virus into the host
(Martinez et al., 2002a).
Although the majority of studies on RNAi-mediated inhibition of infectious
viral diseases have focused on HIV, inhibition of viral replication by RNAi has
been demonstrated in vitro for a number of other RNA viruses including hepatitis
C (HCV), poliovirus, Rous sarcoma virus (RSV), rhesus rotavirus (RRV),
influenza virus, respiratory syncytial virus, dengue virus, coronavirus, as well as
DNA viruses such as human papillomavirus type 16 (HPV-16), hepatitis B (HBV),
and herpes simplex virus (Gitlin and Andino, 2003; Lieberman et al., 2003).
For chronic liver inflammatory diseases such as hepatitis B and hepatitis
C, researchers have used synthetic siRNAs to target against sequences
responsible for transciption and protein-coding regions of the capsid (Kapadia et
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aI., 2003; Shlomai et al., 2003). Their results found up to a 100-fold inhibition for

HCV capsid proteins and a 6-fold decrease in secreted HBV surface antigen in
the serum. HBV is the first virus whose inhibition was demonstrated in vivo using
an animal model (McCaffrey et al., 2003). Thus, experimental data strongly
support a role for the therapeutic potential of RNAi in the treatment of HBV and
HCV infections.
The Influenza and respiratory syncytial viruses are major causes of
infection of the respiratory tract in humans. Several groups have demonstrated
that synthetic siRNA targeting conserved regions of the genome, when
administered by intravenous injection or via intranasal routes, could effectively
inhibit virus production (Ge et al., 2004; Bitko et al., 2005; Zhang et al., 2005).
Severe acute respiratory syndrome (SARS) is a viral respiratory illness that was
first reported in Asia in February 2003 and within a few months spread to more
than two dozen countries in North America, South America, Europe, and Asia.
According to the World Health Organization (WHO), a total of 8,098 people
worldwide became sick and 774 died. A recent study has reported the use of
siRNAs in prophylactic and therapeutic regimens targeting the SARS coronavirus
(SCV) in a Rhesus macaque model (Li et al., 2005a). Their analysis revealed that
siRNAs significantly reduced SARS-like symptoms, diminished SCV viral levels,
and reduced alveoli damage without any evidence of siRNA-induced toxicity.
Currently, there is growing enthusiasm regarding the potential therapeutic
applications of RNAi for cancer. Most human tumors arise from genetic mutations
in genes that encode for proteins regulating cell division, which results in
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uncontrolled cellular growth and differentiation.

Thus, the ability to target the

mutant gene and selectively down regulate expression of abnormal proteins
without affecting the wild-type counterpart provides an attractive and promising
tool in gene therapy. Multiple groups have successfully demonstrated siRNAinduced silencing of cancer-associated genes in vitro. Mutations of the ras
protooncogene are present in a variety of cancers. One study showed the ability
to specifically silence the mutant ras oncogene without affecting the wild-type
copy (Brummelkamp and Bernards, 2003). Other preclinical studies have shown
growth inhibition and apoptosis of cancer cells by RNAi-mediated suppression of
various critical oncogenes or tumor-promoting genes, such as vascular
endothelial growth factor (VEGF), human telomerase (hTR), viral oncogenes
(HPV E6), or translocated oncogenes (bcr-abl) (Butz et al., 2003; Kosciolek et al.,
2003; Scherr et al., 2003; Zhang et al., 2003). Various other in vivo studies have
also effectively utilized RNAi in cases of brain, breast, and ovarian cancer to
reduce tumor formation in animal models (Menendez et a/., 2004; Boado, 2005;
Onodera et al., 2005).
However, similar to other forms of gene-based therapies, there are several
problems associated with the development of siRNA therapeutics. The primary
obstacle is the in vivo delivery of these small molecules to the desired cell type,
tissue, or organ.

Because of their relatively large molecular mass and high

negative charge, RNAs have difficulty crossing the cell membrane on their own.
Two different approaches have been developed to address this concern-1)
direct introduction of chemically modified synthetic siRNAs enhanced for
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improved pharmacokinetic properties or 2) the use of plasmid or viral vectors
containing DNA templates to express siRNA within cells.
Synthetic siRNAs may best be suited for short-term interventions and in
situations in which long-term silencing is not necessary, such as in treatment of
acute viral infections or silencing of pro-inflammatory host molecules in order to
prevent tissue damage (Le. apical periodontitis). In cells that are terminally
differentiated or slow to divide, such as macrophages or osteoclasts, gene
suppression by exogenously administered synthetic siRNA can last up to several
weeks, yet their effect in cells that undergo rapid division is more short-lived
(peaking within 2-3 days, and gone by 1 week), as a result of continuous dilution
of the siRNA with each cell division (Song at a/., 2003). However, the half-life of
unmodified siRNAs in serum is very short (reports vary from minutes to days),
and their cellular uptake is not ideal. The short half-life is primarily due to their
rapid elimination by renal filtration due to their small size (-7kDa) and
degradation by endogenous ribonuclease digestion. Thus, the bioavailability of
unmodified siRNAs is limited under characteristic in vivo conditions, and gene
silencing levels are likely to be insignificant. For this reason, numerous attempts
have been made to chemically modify siRNAs in order to decrease their
susceptibility to serum nuclease attack without sacrificing biological activity,
allowing them to maintain sufficient gene-silencing activity for therapeutic use
(Amarzguioui at a/., 2003; Braasch at a/., 2003; Chiu and Rana, 2003).
Chemical modifications can easily be placed at the terminal ends, within
the backbone, or at the ribose molecules of the siRNA duplex {de Fougerolles at
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al., 2005). Particularly, phosphorothioate modification of the internucleoside

linkage has been shown to improve nuclease stability and is well tolerated within
the siRNA duplex (Levin, 1999; Harborth et al., 2003). Encapsulation of siRNAs
in lipid complexes or liposomes, coupling to fusogenic peptides, or linkage to
antibodies or cell surface receptor ligands may also facilitate better entry into
cells and improve biodistribution by producing potential drug candidates that are
big enough to bypass rapid filtration by the kidney (Manoharan, 2002). Recently,
chemically modified siRNAs covalently linked to cholesterol were shown to
improve binding to blood components, thereby increasing the circulation time of
the siRNAs, and increase delivery to hepatocytes (Lorenz et al., 2004; Soutschek
et al., 2004). A dinitrophenol modification at the terminal ends has been shown

to improve transfection efficiency and enhance intracellular stability in vitro (Liao
and Wang, 2005), and perhaps, of most interest to researchers, peptideconjugates have shown to improve cell permeation properties as well as
sequence-specific targeting (Juliano, 2005). However, chemically synthesized
siRNAs are expensive, which poses some difficulty, when genome-wide RNAi
screens are considered in mammalian cells.
In order to circumvent some of the issues involved with direct siRNA
transfection, several groups have developed vector-based delivery systems that
mediate the production of stable siRNA-like molecules in mammalian cells
(Brummelkamp et al., 2002; Paddison et al., 2002; Paul et al., 2002).

Viral

vectors derived from adenovirus, adeno-associated virus, retrovirus, or lentivirus
can be used for more long-term gene silencing, which would be more effective
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for the treatment of chronic infections such as HIV or hepatitis C. These vectors
are engineered to use RNA-polymerase III promoters to direct the synthesis of
short hairpin RNA (shRNA) molecules, which are intracellularly processed into
molecules resembling siRNA that are identical in sequence to the mRNA being
targeted for suppression. Vector-based production of shRNA in vivo have been
shown to be as effective as in vitro generated synthetic siRNA in suppressing
gene expression, and, additionally, can be used to observe loss-of-function
phenotypes that take longer periods of time to develop (Brummelkamp et a/.,
2002a; Rubinson et a/., 2003; Scherr et a/., 2003a).
Although great progress has been made in the development of genetherapy vectors, there are still a number of concerns about safety and control of
gene expression associated with vector-delivered gene therapy (Thomas et a/.,
2003).

These include efficient transduction of targeted cells, sustained and

efficient gene expression of transduced cells, the danger of malignant
transformation resulting from insertional mutagenesis, as well as host immune or
inflammatory responses to the viral vector itself. Furthermore, the effect of longterm expression of shRNA in mammalian cells is unknown.
Even though the original studies of siRNA silencing suggested high
specificity, several mechanisms have been described with both synthetic and
vector-based siRNA expression that can lead to unintended effects on gene
expression and other unexpected "side effects", all of which need to be carefully
considered when developing RNA-based therapies (Jackson et a/., 2003;
Jackson and Linsley, 2004). One potential complication is that siRNA has the
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ability to trigger the innate immune system. Induction of an interferon response
could potentially cause a global and nonspecific suppression of protein
translation,

particularly

in

highly

sensitive

reporter

cell

lines

at

high

concentrations of siRNAs (Sledz et al., 2003). However, interferon response is
typically induced when the double stranded RNA molecule is greater than 30
base pairs (McManus and Sharp, 2002), which is longer than the 21-23 nt in
length siRNA used in RNA interference.

Another possible source of toxicity

might come from the recognition and binding of siRNAs by Toll-like receptor 3,
which is also a pattern recognition receptor found on immune cells.

Upon

recognition of double stranded RNA molecules, TLR 3 triggers a danger signal
reaction and initiates a pro-inflammatory response (Kariko et al., 2004).

Yet,

chemical modifications of siRNA may be enough to overcome TLR 3 recognition
and signaling, and fortunately, these problems have not been observed in most
animal studies.
Perhaps

a

more

significant

problem

associated

with

siRNA

is

unanticipated "off-target" effects resulting from mRNA cleavage or translational
repression of genes bearing partially complementary sequences to either strand
of the duplex siRNA.

It. was originally believed that siRNA requires almost

complete homology throughout the length of its sequence with the intended
mRNA target for effective RNAi to occur. However, it now appears that as few as
eleven contiguous complementary base pairs of siRNA may be enough to evoke
the off-target effect of RNAi-mediated silencing (Jackson, 2003). Although short
stretches of homology are often inevitable, care must be taken to avoid longer
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stretches which have more considerable effects on gene expression. It is also
possible, in some cases, for the siRNA sense strand to be preferentially selected
by the RISC complex instead of the antisense strand, resulting in inhibition of an
unintended mRNA target (Jackson et al., 2003). However, it may be feasible to
inhibit activity of the sense strand through chemical modification, while
maintaining the functionality of the antisense strand, therefore eliminating this
potential problem (Khvorova et al., 2003; Schwarz et al., 2003; Reynolds et al.,
2004). Furthermore, a recent study found that the majority of off-target effects
associated with nonspecific silencing of gene expression resulted from the lipidbased transfection reagent and not the siRNA (Fedorov et al., 2005). This is in
agreement with others who showed lack of interferon response in mice upon
injection of naked siRNAs (Heidel et al., 2004).

Nonetheless, these issues

highlight the importance of judicious siRNA design and testing of different
sequences in order to choose the one with the best target-specific/off-target
profile. This can be achieved by taking advantage of the wide-ranging databases
of expressed mRNAs that are currently available.

A BLAST search

(http.1lwww.ncbi.nlm.nih.govIBLASD should be performed to identify the most

effective siRNA sequences and to make certain that the sequence is homologous
to the target gene of interest. Additionally, microarray screens should be used to
monitor genome-wide expression profiles (Clarke et al., 2004).
Although it is clear that more progress needs to be made to improve
RNAi-delivery systems and to evaluate off-target effects and other potential
sources of toxicity, it is encouraging to note that there are more than 30

65

pharmaceutical and biotechnology companies that have stated interest in or
currently have an RNAi-based drug development program in progress, and many
have published preliminary data obtained from in vivo and mammalian model
systems validating their projects. Sirna Therapeutics recently completed a Phase
I study of Sirna-027, which is a chemically modified siRNA drug that targets
VEGFR1 in order to treat age-related macular degeneration (AMD), results from
which were reported at the American Society of Gene Therapy conference in
June 2005 (Whelan, 2005).

They have also collaborated with Protiva

Biotherapeutics for work relating to treatment of hepatitis B infection (Morrissey

et al., 2005; Morrissey et al., 2005b). Alnylam Pharmaceuticals has partnered
with Norvartis, Merck, and Medtronic for drug development projects targeting
multiple diseases, and has published preliminary results using anti-ApoB siRNAs
for treatment of hypercholesterolemia (Soutschek et al., 2004). Their next target
is pandemic influenza, for which they filed an Investigational New Drug
Application (IND) with the Food and Drug Administration (FDA) in 2006. Nastech
Pharmaceuticals, working in conjunction with the Mayo Clinic, presented
preclinical results at the November 2005 American College of Rheumatology
meeting on the use of an anti-TNF-a siRNA for treatment of rheumatoid arthritis
(Behlke, 2006). Calando Pharmaceuticals has collaborated with the Children's
Hospital of Los Angeles to describe the use of siRNA to treat Ewing's sarcoma
(Hu-Lieskovan et al., 2005). Numerous studies have been published by
Intradigm, in collaboration with other pharmaceutical companies, using siRNA to
treat cancer, arthritis, ocular, and viral diseases (Kim et al., 2004; Schiffelers et
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al., 2004; Li et al., 2005; Schiffelers et al., 2005; Schiffelers et al., 2005b), and

Abbott and NeoPharm have both investigated the potential of siRNA-based
therapeutics in a murine cancer model system (Li et al., 2005; Pal et al., 2005).
However, it should be noted that Fomiversen (Vitravene) manufactured by ISIS
Pharmaceuticals, which is a drug for the treatment of CMV retinitis, is the only
existing FDA-approved siRNA-based drug available on the market at this time.
Not enough may be known about the potential negative effects of
prolonged or repetitive use of RNAi on normal cellular metabolism when used for
treatment of chronic diseases. It is possible that toxicities may not show up for
months, or perhaps years. Clearly, such issues require further long-term studies
in therapeutically relevant animal models of RNA interference.

Nonetheless,

considering the immense interest and the rapid pace by which RNAi research is
advancing, it is foreseeable that this relatively new scientific discovery will have a
dramatic impact on the development of an innovative and new class of drugs
whose therapeutic potential seems enormous.
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Conclusion
RNA interference is a unique and powerful tool that can be used for the
study gene function by suppressing its expression.

It is also a fast and

inexpensive method to selectively silence a gene product in complex biological
systems whose clinical potential for treatment of various diseases and disorders
has been demonstrated. Using RNAi, with specific NFATc1 and TLR4 siRNA we
were able to successfully:
1. Deliver siRNA into the cytoplasm of monocytes and osteoclasts
with high efficiency.
2. Demonstrate a significant reduction in the expression of TLR4 and
NFATc1 in cells that were transfected with specific siRNA.
3. Demonstrate a significant reduction of TNF-a and IL-6 production in
transfected monocytes in response to LPS stimulation.
4. Demonstrate a significant reduction in the number of mature
osteoclasts formed in response to LPS stimulation.
5. Demonstrate a significant reduction in osteoclast specific gene
expression and lower levels of TNF-a production in response to
LPS stimulation.

Although much work still remains in improving the delivery, specificity, and
effectiveness of siRNAs, RNAi-based therapies have emerged as highly
promising prospects with applications for a wide spectrum of diseases.
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Statistical Analysis
Oneway analysis of variance for IL-6 ELISA in monocytes
Descriptives
Final (uQ/ml)

N
control
TLR4
NFATc1
Total

3
3
3
9

Std.
Deviation

Mean
9.52000
3.48000
5.11333
6.03778

2.047144
.784602
.984344
2.960548

Std.
Error
1.181919
.452990
.568311
.986849

95% Confidence Interval
for Mean
Lower
Upper
Bound
Bound
4.43461
14.60539
1.53094
5.42906
2.66809
7.55858
3.76210
8.31346

Minimum

Maximum

7.180
2.580
4.420
2.580

10.980
4.020
6.240
10.980

Test of Homogeneity of Variances
Final (ug/ml)
Levene
Statistic
3.246

df1

df2
2

Sig.
.111

6

ANOVA
Final (ug/ml)

Between Groups
Within Groups
Total

Sum of
Squares
58.568
11.551
70.119

df
2
6
8

Mean Square
29.284
1.925

F
15.212

Sig.
.004
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Post Hoc Tests for IL-6 production in monocytes
Multiple Comparisons
DeDendent Variable: Final (uQ/ml)

Tukey HSD

(I) LPS +
control

TLR4
NFATc1
control

LSD

TLR4
NFATc1

(J) LPS +
TLR4
NFATc1
control
NFATc1
control
TLR4
TLR4
NFATc1
control
NFATc1
control
TLR4

Mean
Difference
(I-J)
6.040000·
4.406667·
-6.040000·
-1 .633333
-4.406667*
1.633333
6.040000·
4.406667·
-6.040000·
-1 .633333
-4.406667*
1.633333

Std . Error
1.132876
1.132876
1.132876
1.132876
1.132876
1.132876
1.132876
1.132876
1.132876
1.132876
1.132876
1.132876

Sig.
.004
.019
.004
.380
.019
.380
.002
.008
.002
.199
.008
.199

95% Confidence Interval
Lower Bound
Upper Bound
2.56403
9.51597
7.88264
.93069
-9.51597
-2.56403
-5.10931
1.84264
-7.88264
-.93069
-1 .84264
5.10931
3.26795
8.81205
1.63462
7.17871
-8.81205
-3.26795
-4.40538
1.13871
-7.17871
-1 .63462
-1.13871
4.40538

*. The mean difference is significant at the .05 level.

Homogeneous Subsets (IL-6 production in monocytes)
Final (ug/ml)

=

Tukey Hsoa

LPS +
TLR4
NFATc1
control
Sig.

N
3
3
3

Subset for alpha .05
1
2
3.48000
5.11333
9.52000
.380
1.000

Means for groups in homogeneous subsets are displayed.
a. Uses Harmonic Mean Sample Size

= 3.000.

Graph (IL-6 production in monocytes)
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Oneway analysis of variance TNF - alpha ELISA in monocytes
Descriptives
Final (ug/ml\

control
siRNA
TLR4
siRNA
NFATc1
siRNA
Total

Std.
Error

Std.
Deviation

95% Confidence Interval
for Mean
Lower
Upper
Bound
Bound

N

Mean

Minimum

Maximum

3

23.49000

.980064

.565840

21.05539

25.92461

22.695

24.585

3

15.16500

1.005336

.580431

12.66761

17.66239

14.145

16.155

3

18.31000

1.429047

.825061

14.76005

21.85995

16.725

19.500

9

18.96633

3.775642

1.256614

16.08596

21.89070

14.145

24.585

Test of Homogeneity of Variances
Final (ug/ml)
Levene
Statistic
.445

df1

Sig.
.660

df2
2

6

ANOVA
Final (ug/ml)

Between Groups
Within Groups
Total

Sum of
Squares
106.029
8.027
114.056

df
2
6
8

Mean Square
53.015
1.338

F
39.628

Sig.
.000
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Post Hoc Tests for TNF-alpha production in monocytes
Multiple Comparisons
Dependent Variable: Final (ug/ml)
Mean
Difference
Tukey HSD

(I) LPS +

(J) LPS +

control siRNA

TLR4siRNA
NFATc1 siRNA
control siRNA
NFATc1 siRNA
control siRNA
TLR4siRNA
TLR4siRNA
NFATc1 siRNA
control siRNA
NFATc1 siRNA
control siRNA
TLR4siRNA

TLR4 siRNA
NFATc1 siRNA
LSD

control siRNA
TLR4 siRNA
NFATc1 siRNA

(I-J)

8.325000·
5.180000·
-8.325000·
-3.145000·
-5.180000·
3.145000·
8.325000·
5.180000·
-8.325000·
-3.145000·
-5.180000·
3.145000·

Std. Error
.944387
.944387
.944387
.944387
.944387
.944387
.944387
.944387
.944387
.944387
.944387
.944387

Sig .
.000
.004
.000
.036
.004
.036
.000
.002
.000
.016
.002
.016

95% Confidence Interval
Lower Bound
Upper Bound
5.42736
11 .22264
2.28236
8.07764
-11.22264
-5.42736
-.24736
-6.04264
-8.07764
-2.28236
.24736
6.04264
6.01417
10.63583
2.86917
7.49083
-10.63583
-6.01417
-5.45583
-.83417
-2.86917
-7.49083
.83417
5.45583

• . The mean difference IS Significant at the .05 level.

Homogeneous Subsets (TNF-alpha production in monocytes)
Final (ug/ml)

Tukey HSDa

LPS +
TLR4 siRNA
NFATc1 siRNA
control siRNA
Sig.

N
3
3
3

Subset for alpha
1
2
15.16500
18.31000
1.000

1.000

=.05
3

23.49000
1.000

Means for groups in homogeneous subsets are displayed.
a. Uses Harmonic Mean Sample Size

=3.000.

Graph (TNF-alpha production in monocytes)
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Oneway analysis of variance IL-1 alpha ELISA in monocytes

Descriptives
Dilution value

control
siRNA
TLR4
siRNA
NFATc1
siRNA
Total

Std.
Deviation

Std.
Error

95% Confidence Interval
for Mean
Lower
Upper
Bound
Bound

N

Mean

Minimum

Maximum

3

30.6667

3.21455

1.85592

22.6813

38.6521

27.00

33.00

3

25.6667

3.78594

2.18581

16.2619

35.0715

23.00

30.00

3

32.6667

2.51661

1.45297

26.4151

38.9183

30.00

35.00

9

29.6667

4.18330

1.39443

26.4511

32.8822

23.00

35.00

Test of Homogeneity of Variances
Dilution value
Levene
Statistic
.589

df2

df1
2

Sig.
.584

6

ANOVA

Dilution value

Between Groups
Within Groups
Total

Sum of
Squares
78.000
62.000
140.000

df
2
6
8

Mean Square
39.000
10.333

F
3.774

Sig.
.087
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Post Hoc Tests for IL-1-alpha production in monocytes
Multiple Comparisons
Dependent Variable: Dilution value
Mean
Difference
Tukey HSD

(I) LPS +

(J) LPS +

(I-J)

control siRNA

TLR4 siRNA
NFATc1 siRNA
control siRNA
NFATc1 siRNA
control siRNA
TLR4 siRNA
TLR4 siRNA
NFATc1 siRNA
control siRNA
NFATc1 siRNA
control siRNA
TLR4 siRNA

5.00000
-2.00000
-5.00000
-7. 00000
2.00000
7.00000
5.00000
-2.00000
-5. 00000
-7.00000'
2.00000
7.00000'

TLR4 siRNA
NFATc1 siRNA
control siRNA

LSD

TLR4 siRNA
NFATc1 siRNA

Std. Error
2.62467
2.62467
2.62467
2.62467
2.62467
2.62467
2.62467
2.62467
2.62467
2.62467
2.62467
2.62467

Sig.
.217
.738
.217
.083
.738
.083
.105
.475
.105
.037
.475
.037

95% Confidence Interval
Lower Bound
U~er Bound
-3.0532
13.0532
-1 0.0532
6.0532
-13.0532
3.0532
-15.0532
1.0532
-6.0532
10.0532
-1.0532
15.0532
-1.4223
11.4223
-8.4223
4.4223
-11.4223
1.4223
-13.4223
-.5777
-4.4223
8.4223
.5777
13.4223

'. The mean difference IS Significant at the .05 level.

Homogeneous Subsets (IL-1-alpha production in monocytes)
Dilution value
Subset
for alpha
.05
1
25.6667
30.6667
32.6667
.083

=

Tukey Hsoa

LPS +
TLR4 siRNA
control siRNA
NFATc1 siRNA
Sig.

N
3
3
3

Means for groups in homogeneous subsets are displayed.
a. Uses Harmonic Mean Sample Size

=3.000.

Graph (IL-1-alpha production in monocytes)
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Oneway - Number of Osteoclasts Formed
Oescriptives
Osteoclasts formed

N
control siRNA
TLR4 siRNA
NFATcl siRNA
Total

Std.
Deviation
24.87971
57.88782
39.00000
96.31070

Mean
356.0000
234.0000
152.0000
247.3333

3
3
3
9

Std. Error
14.36431
33.42155
22.51666
32.10357

95% Confidence Interval for
Mean
Upper Bound
Lower Bound
294.1954
417.8046
90.1987
377.8013
55.1186
248.8814
173.3024
321.3643

Minimum
329.00
188.00
128.00
128.00

Maximum
378.00
299.00
197.00
378.00

AN OVA

Osteoclasts formed
Sum of
Squares
Between Groups
Within Groups
Total

df

Mean Square

63224.00
10982.00
74206.00

2
6
8

31612.000
1830.333

F

Sig.

17.271

.003

Post Hoc Tests for Number of Osteoclasts Formed
Multiple Comparisons
Dependent Variable: Osteoclasts formed
Mean
Difference
(I) LPS

Tukey HSD

+

(J) LPS

control siRNA
TLR4 siRNA
NFATcl siRNA

LSD

control siRNA
TLR4 siRNA
NFATcl siRNA

'. The mean difference

IS

+

TLR4 siRNA
NFATcl siRNA
control siRNA
NFATcl siRNA
control siRNA
TLR4 siRNA
TLR4 siRNA
NFATcl siRNA
control siRNA
NFATcl siRNA
control siRNA
TLR4 siRNA

(I-J)

122.00000'
204.00000'
-122.00000'
82.00000
-204.00000'
-82.00000
122.00000'
204.00000'
-122.00000'
82.00000
-204.00000'
-82.00000

Std. Error
34.93168
34.93168
34.93168
34.93168
34.93168
34.93168
34.93168
34.93168
34.93168
34.93168
34.93168
34.93168

Sig.
.030
.003
.030
.124
.003
.124
.013
.001
.013
.057
.001
.057

95% Confidence Interval
Upper Bound
Lower Bound
14.8200
229.1800
96.8200
311.1800
-229.1800
-14.8200
-25.1800
189.1800
-311.1800
-96.8200
-189.1800
25.1800
36.5253
207.4747
118.5253
289.4747
-207.4747
-36.5253
-3.4747
167.4747
-289.4747
-118.5253
-167.4747
3.4747

significant at the .05 level.
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Homogeneous Subsets
Osteoclasts formed

=

Tukey HSDs

LPS +
NFATc1 siRNA
TLR4 siRNA
control siRNA
Sig.

Subset for alpha .05
1
2
152.0000
234.0000
356.0000
.124
1.000

N
3
3
3

Means for groups in homogeneous subsets are displayed.
a. Uses Harmonic Mean Sample Size 3.000.

=

Oneway - Osteoclast TNF-alpha level
Descriptives
TNFalpha levels
al for
N
control siRNA
TLR4 siRNA
NFATc1 siRNA
Total

3
3
3
9

Mean
3.8000
2.6000
1.8800
2.7600

Std.
Deviation
.28844
.31749
.13856
.86971

Mean
St
.16653
.18330
.08000
.28990

3.0835
1.8113
1.5358
2.0915

er Bound
4.5165
3.3887
2.2242
3.4285

Minimum
3.48
2.24
1.80
1.80

Maximum
4.04
2.84
2.04
4.04

ANOVA

TNF aipi
I ha Ieves

Between Groups
Within Groups
Total

Sum of
Squares
5.645
.406
6.051

df
2
6
8

Mean SQuare
2.822
.068

F
41.669

Sig.
.000
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Post Hoc Tests for Osteoclast TNF-alpha Production
Multiple Comparisons
Dependent Variable: TNFalpha levels
Mean
Difference
Tukey HSD

(I) LPS+
control siRNA
TLR4 siRNA
NFATc1 siRNA

LSD

control siRNA
TLR4 siRNA
NFATc1 siRNA

(I.J)

(J) LPS +

Std. Error
1.20000'
.21250
1.92000'
.21250
-1.20000'
.21250
.72000'
.21250
-1.92000'
.21250
-.72000'
.21250
1.20000'
.21250
1.92000'
.21250
-1.20000'
.21250
.72000'
.21250
-1.92000'
.21250
-.72000'
.21250

TLR4siRNA
NFATc1 siRNA
control siRNA
NFATc1 siRNA
control siRNA
TLR4 siRNA
TLR4 siRNA
NFATc1 siRNA
control siRNA
NFATc1 siRNA
control siRNA
TLR4 siRNA

Sig.
.003
.000
.003
.034
.000
.034
.001
.000
.001
.015
.000
.015

95% Confidence Interval
Upper80und
Lower Bound
.5480
1.8520
1.2680
2.5720
-.5480
·1.8520
1.3720
.0680
-2.5720
-1.2680
-1.3720
-.0680
1.7200
.6800
1.4000
2.4400
-.6800
-1.7200
.2000
1.2400
·2.4400
-1.4000
-1.2400
-.2000

'. The mean difference IS significant at the .05 level.

Homogeneous Subsets
TNFalpha levels

Tukey HSDa

LPS +
NFATc1 siRNA
TLR4 siRNA
control siRNA
Sig.

N

3
3
3

Subset for alpha = .05
1
2
3
1.8800
2.6000
3.8000
1.000
1.000
1.000

Means for groups in homogeneous subsets are displayed.
a. Uses Harmonic Mean Sample Size::: 3.000.
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Graph (Osteoclast TNF-alpha Production)
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